| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IL-15 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于IL-15抗体的参考文献摘要示例(内容为模拟，非真实文献)：
1. **标题**：*Targeting IL-15 with a neutralizing antibody enhances antitumor immunity in solid tumors*
**作者**：Miller JS, et al.
**摘要**：研究开发了一种靶向IL-15的中和抗体(ADU-214)，通过阻断IL-15信号通路抑制肿瘤微环境中效应T细胞和NK细胞的异常激活。临床前实验表明，该抗体可显著抑制黑色素瘤和结直肠癌小鼠模型的肿瘤生长，并增强PD-1抑制剂的疗效。
2. **标题**：*IL-15 receptor-targeted antibody-drug conjugate for T-cell leukemia therapy*
**作者**：Dubois S, et al.
**摘要**：文章报道了一种靶向IL-15受体β链的抗体-药物偶联物(ADC)，通过特异性结合高表达IL-15R的T细胞白血病细胞，释放细胞毒性药物。体外和体内实验显示，该ADC可选择性杀伤白血病细胞，同时减少对正常T细胞的影响。
3. **标题**：*A humanized anti-IL-15 monoclonal antibody ameliorates autoimmune arthritis in preclinical models*
**作者**：Bergamaschi C, et al.
**摘要**：研究利用人源化IL-15抗体(AMG-714)阻断IL-15与受体结合，显著减轻类风湿性关节炎小鼠模型的关节炎症和骨侵蚀，表明靶向IL-15可能是治疗自身免疫疾病的有效策略。
4. **标题**：*IL-15 blockade reshapes the tumor microenvironment and synergizes with checkpoint inhibitors*
**作者**：Mishra A, et al.
**摘要**：通过拮抗IL-15信号，研究者发现肿瘤相关巨噬细胞(TAMs)的促癌表型被抑制，同时CD8+ T细胞浸润增加。联合抗PD-1治疗在肺癌模型中显示出协同抗肿瘤效果。
(注：以上文献信息为示例性内容，实际引用需查询真实数据库如PubMed。)
Interleukin-15 (IL-15) is a pleiotropic cytokine critical for immune system regulation, particularly in the survival, proliferation, and activation of natural killer (NK) cells, CD8+ memory T cells, and innate lymphoid cells. It shares structural and functional similarities with IL-2 but has distinct roles in maintaining immune homeostasis and promoting anti-tumor immunity. Dysregulated IL-15 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis, celiac disease) and cancer progression, making it a therapeutic target.
IL-15 antibodies are designed to modulate this pathway. Neutralizing antibodies can block IL-15 binding to its receptor (IL-15Rα/γc), suppressing pro-inflammatory responses in autoimmune conditions. Conversely, agonist antibodies or IL-15/IL-15Rα complexes are explored in immunotherapy to enhance NK and T cell activity against tumors. Challenges include optimizing antibody specificity, pharmacokinetics, and minimizing off-target effects. For example, monoclonal antibodies like AMG 714 (anti-IL-15) have shown promise in celiac disease trials, while engineered IL-15 superagonists (e.g., N-803) are being tested in cancer. Research continues to address toxicity concerns and improve delivery mechanisms, highlighting IL-15's dual role as a therapeutic target or enhancer depending on disease context.
×
